Table 1.
Characteristics of 1042 women with a serous borderline ovarian tumor (SBT) in Denmark 1978–2002.
| Overall (n =1042)
|
Stage I (n=886)
|
Stages II–IV (n=145)
|
p-value
|
||||
|---|---|---|---|---|---|---|---|
| n | (%) | n | (%) | n | (%) | Stage I versus II–IV#,* | |
| Clinical features | |||||||
| FIGO stage | – | ||||||
| Stage I | 886 | (85.0) | – | – | – | – | |
| Stage II | 69 | (6.6) | – | – | – | – | |
| Stage III | 75 | (7.2) | – | – | – | – | |
| Stage IV | 1 | (0.1) | |||||
| Undefinable stage | 11 | (1.1) | – | – | – | – | |
| Median age (range) | 50 | (16–97) | 51 | (16–97) | 45 | (17–89) | 0.2 |
| Median tumor size (cm) (range)§ | 9 | (1–35) | 9 | (1–35) | 10 | (3–30) | 0.7 |
| Laterality | <0.0001 | ||||||
| Unilateral | 680 | (65.3) | 630 | (71.1) | 44 | (30.3) | |
| Bilateral | 362 | (34.7) | 256 | (28.9) | 101 | (69.7) | |
| Surface involvement | <0.0001* | ||||||
| No | 626 | (60.1) | 596 | (67.3) | 29 | (20.0) | |
| Yes | 387 | (37.1) | 266 | (30.0) | 112 | (77.2) | |
| Unknown | 29 | (2.8) | 24 | (2.7) | 4 | (2.8) | |
| Capsule rupture | 1.0* | ||||||
| No | 664 | (63.7) | 566 | (63.9) | 93 | (64.1) | |
| Yes | 250 | (24.0) | 213 | (24.0) | 33 | (22.8) | |
| Unknown | 128 | (12.3) | 107 | (12.1) | 19 | (13.1) | |
| Ascites | <0.0001* | ||||||
| No | 751 | (72.1) | 685 | (77.3) | 63 | (43.5) | |
| Yes | 252 | (24.2) | 168 | (19.0) | 77 | (53.1) | |
| Unknown | 39 | (3.7) | 33 | (3.7) | 5 | (3.4) | |
| Pathologic features | |||||||
| Tumor type | 0.0009 | ||||||
| SBT/APST | 961 | (92.2) | 828 | (93.4) | 124 | (85.5) | |
| Noninvasive LGSC (>5 mm) | 81 | (7.8) | 58 | (6.5) | 21 | (14.5) | |
| Implants | – | ||||||
| No | 886 | (85.0) | 886 | (100.0) | 0 | (0.0) | |
| Yes | 145 | (13.9) | 0 | (0.0) | 145 | (100.0) | |
| Noninvasive | 121 | (83.4) | 0 | (0.0) | 121 | (83.4) | |
| Invasive | 24 | (16.6) | 0 | (0.0) | 24 | (16.6) | |
| Undefinable stage | 11 | (1.1) | 0 | (0.0) | 0 | (0.0) | |
| Treatment features | |||||||
| Surgical treatment | – | ||||||
| USO | 143 | (14%) | 134 | (15%) | 8 | (6%) | |
| BSO | 74 | (7%) | 65 | (7%) | 7 | (5%) | |
| Other surgical treatment | 30 | (3%) | 26 | (3%) | 2 | (1%) | |
| USO/BSO + Hysterectomy | 795 | (76%) | 661 | (75%) | 128 | (88%) | |
| Chemotherapy | – | ||||||
| No | 833 | (80.0) | 770 | (86.9) | 62 | (42.7) | |
| Yes | 191 | (18.3) | 102 | (11.5) | 80 | (55.2) | |
| Unknown | 18 | (1.7) | 14 | (1.6) | 3 | (2.1) | |
Abbreviations: International Federation of Gynecology and Obstetrics (FIGO); atypical proliferative serous tumor (APST); low-grade serous carcinoma (LGSC); unilateral salpingo-oophorectomy (USO); bilateral salpingo-oophorectomy (BSO); number (n).
§
Based on biggest tumor size (cm) and 1014 women (97%) since 28 women did not have tumor size information (3%).
#
Excluding 11 women (1%) with undefinable stage.
*
Excluding women with unknown information.